US 12370257
Materials and methods of treating MHC-I-opathy risk haplotypes
granted A61KA61K31/7088A61K31/713
Quick answer
US patent 12370257 (Materials and methods of treating MHC-I-opathy risk haplotypes) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K31/7088, A61K31/713, A61K39/3955, A61K45/06